The relationship between overexpression of DLEU2 and worse patient survival rate was also confirmed in esophageal, head-neck, kidney, liver cancers, and pheochromocytoma/paraganglioma (Fig. S7). This evidence concerns the gene DLEU2 and hereditary pheochromocytoma-paraganglioma.